A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

Also called NCT04992065

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 267 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04992065
  • EudraCT 2020-002630-32
Main results
  • PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial The lancet. Diabetes & endocrinology, 2024-03 DOI, PubMed 38310920

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Germany, Greece, Japan, Netherlands, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04992065. Randomized; double masking; primary purpose treatment. Start 2021-08-03 (actual); primary completion 2022-04-26 (actual). Results posted on 2025-06-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
NNC0385-0434 A 15 mg
Intervention (Drug)
NNC0385-0434 A 40 mg
Intervention (Other)
Placebo I A (for NNC0385-0434 A 15 mg)
Intervention (Drug)
NNC0385-0434 A 100 mg
Intervention (Other)
Placebo I A (for NNC0385-0434 A 40 mg)
Intervention (Other)
Placebo II A (for NNC0385-0434 A 100 mg)
Intervention (Drug)
Evolocumab 140 mg/mL, Repatha®
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04992065
Content hash
360a8072195007b79604717e6f877d841dd8a88b952a22ae568865f727e36185